Because αvβ3 integrin, a cell surface receptor, is dramatically upregulated during neovascularization in the case of most cancers, targeting of integrin receptors by either αvβ3 integrin antibody or anti-angiogenic peptides (RGD/NGR), showed some exciting therapeutic results. This evidence concerns the gene CD177 and cancer.